Celgene (JOBS) Cancer Pill to Triple Sales on Data Threatening Johnson & Johnson (JOBS)

Bloomberg -- Celgene Corp. can more than triple sales for its best-selling cancer pill Revlimid on new data that may convince doctors to choose the drug as a first option over Johnson & Johnson’s intravenous medicine, Velcade.